The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.
SEL-212 fails to beat Krystexxa in phase II, but why did Sobi pay $100m for the asset in June and then put it into phase III?
In Dapa-CKD, Farxiga-treated patients without diabetes did numerically better than those with diabetes.
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.